Schwartz-Reisman Liver Research Centre, University Health Network, Toronto, ON, Canada; Department of Immunology, University of Toronto, Toronto, ON, Canada.
Schwartz-Reisman Liver Research Centre, University Health Network, Toronto, ON, Canada; Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada.
Antiviral Res. 2024 Jun;226:105893. doi: 10.1016/j.antiviral.2024.105893. Epub 2024 Apr 26.
With the increasing momentum and success of monoclonal antibody therapy in conventional medical practices, there is a revived emphasis on the development of monoclonal antibodies targeting the hepatitis B surface antigen (anti-HBs) for the treatment of chronic hepatitis B (HBV) and hepatitis D (HDV). Combination therapies of anti-HBs monoclonal antibodies, and novel anti-HBV compounds and immunomodulatory drugs presenting a promising avenue to enhanced therapeutic outcomes in HBV/HDV cure regimens. In this review, we will cover the role of antibodies in the protection and clearance of HBV infection, the association of anti-HBV surface antigen antibodies (anti-HBs) in protection against HBV and how antibody effector functions, beyond neutralization, are likely necessary. Lastly, we will review clinical data from previous and ongoing clinical trials of passive antibody therapy to provide a state-of-the-are perspective on passive antibody therapies in combinations with additional novel agents.
随着单克隆抗体疗法在常规医学实践中势头的增强和取得的成功，人们重新重视开发针对乙型肝炎表面抗原 (抗-HBs) 的单克隆抗体，用于治疗慢性乙型肝炎 (HBV) 和乙型肝炎 D (HDV)。抗-HBs 单克隆抗体与新型抗 HBV 化合物和免疫调节剂联合治疗为 HBV/HDV 治愈方案带来了增强治疗效果的有前途的途径。在这篇综述中，我们将介绍抗体在保护和清除 HBV 感染中的作用、抗 HBV 表面抗原抗体 (抗-HBs) 在预防 HBV 感染中的作用，以及抗体效应功能（除中和作用外）可能是必要的。最后，我们将回顾以前和正在进行的被动抗体治疗临床试验的临床数据，提供关于被动抗体治疗与其他新型药物联合使用的最新观点。
